CN1064263C - Suxiao Xinmaisu drug for curing angiocardiopathy - Google Patents
Suxiao Xinmaisu drug for curing angiocardiopathy Download PDFInfo
- Publication number
- CN1064263C CN1064263C CN96102904A CN96102904A CN1064263C CN 1064263 C CN1064263 C CN 1064263C CN 96102904 A CN96102904 A CN 96102904A CN 96102904 A CN96102904 A CN 96102904A CN 1064263 C CN1064263 C CN 1064263C
- Authority
- CN
- China
- Prior art keywords
- medicine
- semen
- culture medium
- mushroom
- bull
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a Suxiaoxinmaisu medicine for curing the diseases of a cardiovascular system. The zymotic substances of a culture medium and the mycelia of ganoderma, edible tree fungus, tuckahoe straw mushroom, blood ganoderma, mushroom, golden mushroom, champignon, hericium cap fungus and tremella which are cultured by the culture medium for beans are used as raw materials, and living sporophores are used as main raw materials; the present invention is prepared from the technology of bacterial strain selection, mycelia cultivation, sporophore selection, main raw material preparation, lixiviation, concentration, finished product production, etc. The product enriches natural biologic active materials, polysaccharide, nucleic acids, vitamins, unsaturated fatty acids, nineteen amino acids and tens of trace elements, such as germanium, iodine, zinc, chromium, selenium, etc., and has no toxic or side effect. The present invention has the characteristics of obvious, long and quick effect, short course of treatment, etc. for the disease of a cardiovascular system via clinical indication.
Description
The invention belongs to the preparation method of medicine, particularly a kind of preparation method for the treatment of the cardiovascular system diseases medicine.
As everyone knows, the mycelium of human use beans, medicinal fungi and sporophore medicinal efficacy are treated some disease and are of long duration, and this is all on the books on medicine book and relevant publication.For example treat the cardiovascular system diseases aspect, just record in " Fujian medicine will ": Semen sojae atricolor has removing heat from blood, detoxifcation, dampness removing, detumescence effect; Semen arachidis hypogaeae has removing heat from blood, the effect of stopping blooding, dispel the wind, dehumidify; Semen phaseoli radiati has heat clearing away, detoxicating functions; Semen Phaseoli has heat clearing away, detoxifcation, damp eliminating, diuretic, promoting the circulation of blood, detumescence effect.Record at " Chinese medicinal fungi ": Poria is controlled the cardiopalmus effect; Ganoderma has treatment coronary heart disease, cardiopalmus, dizzy effect; The obstructed effect of heart arteries and veins is invigorated blood circulation, stops blooding, treated to Auricularia, Tremella; Mushroom has treatment hypertension; Lentinus Edodes has cholesterol reducing effect or the like.In clinical practice, these beans and Mycophyta are many to be used with single dry product infusion; Or single and other Chinese herbal medicine compatibilities uses.On biotechnology and medical angle, beans might as well, Mycophyta might as well, make and singlely or compound behind the dry product carry out infusion and be used and have following shortcoming: the one, reduce easily and weaken original biological activity effect that it includes; The 2nd, the active substance total amount of its medicinal component significantly descend (minimizing), the growth of effective percentage, obvious effective rate and improvement rate all is restricted so it is cured the disease, the disease of treatment is also more single, the drug action that does not have broad spectrum activity, and quick-acting is poor, the curative effect cycle is long, the specific demand of incompatibility cardiovascular system diseases.The comprehensive mechanism of curing the disease of utilizing beans, fungal mycelium, fungus sporophore is used in the clinical treatment cardiovascular system diseases and had not yet to see report with effect, particularly utilizes mutual compatibility of active ingredient of its biological work material to be prepared into medicine.
The object of the invention is to provide a kind of treatment cardiovascular system diseases medicine.
According to the object of the invention, the disclosed treatment cardiovascular system diseases of inventor medicine, its main material is by Ganoderma, Auricularia, Poria, Volvariella volvacea (Bull.Ex Franch.) Singer, the blood sesame, mushroom, JINZHENGU, Lentinus Edodes, Hericium erinaceus (Bull. Ex Fr.) Pers., Pleurotus ostreatus, each plant demand of the mycelium of Tremella is 5-15%, Ganoderma, Auricularia, Poria, Volvariella volvacea (Bull.Ex Franch.) Singer, the blood sesame, mushroom, JINZHENGU, Lentinus Edodes, Hericium erinaceus (Bull. Ex Fr.) Pers., Pleurotus ostreatus, each plant demand of live body sporophore of Tremella is 5-15%, Semen Glycines, Semen sojae atricolor, Semen phaseoli radiati, Semen arachidis hypogaeae, each plant demand of Semen Phaseoli is that the beans culture medium zymolite of 5-15% composition is formulated, and its step of preparation process comprises strain breeding thereof, the preparation of beans culture medium, mycelium is cultivated, sporophore is chosen, the main material preparation, lixiviate, concentrate, finished product is made.
Below preparation technology of the present invention is specifically described.
One, strain breeding thereof:
1, bacterial strain is chosen: as bacterial strain of the present invention is to select for use the medicable Mycophyta of cardiovascular system diseases is had: Ganoderma, Auricularia, Poria, Volvariella volvacea (Bull.Ex Franch.) Singer, blood sesame, mushroom, JINZHENGU, Lentinus Edodes, Hericium erinaceus (Bull. Ex Fr.) Pers., Pleurotus ostreatus, Tremella etc.
2, bacterial strain is cultivated: will above-mentionedly choose in the slant tube that bacterial strain inserts the potato culture behind the autoclaving respectively conventional cultivation; Conscientiously screening no living contaminants, mycelial growth rate fast, climb that wall energy power is strong, increment is many, the mycelium kink early and many bacterial strains as mycelium propagation cultivation use.
Two, beans culture medium preparation:
Mycelial beans culture medium preparation: choosing has Semen arachidis hypogaeae, Semen Glycines, Semen Phaseoli, Semen sojae atricolor, each 20% amount wash clean of Semen phaseoli radiati of germinating capacity, soak under 20 ℃ of conditions 48 hours drops anhydrate add behind the branch calcium sulfate, glucose each 2%, the pH value nature, divide in the container of packing into behind the mix homogeneously and seal with tampon, through 1.1kg/cm as in the wide-mouth dried mushroom bottle
2Sterilized 60 minutes, and promptly can be used as after the cooling and cultivate mycelial culture medium.
Three, mycelium is cultivated: above-mentioned bacterial strains is inserted the above-mentioned beans culture medium that has prepared, carry out mycelial growth amount propagation according to conventional condition of culture and cultivate, treat that mycelium covers with substrate and gets final product.
Four, choosing of sporophore: refer to the bacterial strain that the invention described above is used as fungus sporophore of the present invention; Sporophore should be chosen the not fresh mushroom ear product of seiospore.
Five, main material is equipped with: main material prescription of the present invention is to meet each 5-15% of above-mentioned fungal mycelium (containing beans culture separately), each 5-15% of above-mentioned fungus sporophore, mycelium (the containing beans culture separately) mixture that to choose by prescription and each sporophore chips mixture of taking by weighing by prescription be according to each amount half-and-half, fully mix the main material mixture.
Six, lixiviate:
1, lixiviating solution preparation: lixiviating solution of the present invention is by cellulase, papain, each 0.1-0.5% of pectase, vinegar, each 0.5-2% of egg albumen, and Rhizoma Zingiberis Recens fragment, each 1-6% of Bulbus Allii fragment, adding distil water to 100% promptly is mixed with lixiviating solution.
2, lixiviate: the main material mixture of above-mentioned preparation is placed in the stainless steel water bath, poured into lixiviating solution, the lixiviate liquid measure is regulated pH value to 4.5-5 being advisable by the submergence raw mix with Vc.In 45 ° of-65 ℃ of temperature, extract successively 3 times, each 3 hours, at every turn all with slurry slag separator separate lixiviating solution, merge lixiviating solution.
Seven, concentrate: according to producing medicine oral liquid and medicament capsule, different process requirement, it is standby that lixiviating solution is concentrated into the concentrated solution that the capsule of dense oral liquid that the molten liquid that contracts of soluble solid content 〉=12% uses and soluble solid content 〉=20% uses respectively.
Eight, finished product is produced:
1, oral liquid: the concentrated solution 10000ml that the said medicine oral liquid is used adds protein sugar 35g, Catergen 00g, regulates sour-sweet degree taste appropriateness and promptly makes oral liquid, divides the sterile chamber of packing into promptly to get the oral liquid finished product.
2, capsule: with the said medicine capsule, with concentrated solution put vacuum in the stainless steel disc (65 ℃ of 0.1MPa) dry, be ground into powdery, add again the powdery amount 8% vitamin C amount uniform mixing rear packing, medicament capsule is put 65 ℃ of sterilization treatment at last, promptly make capsule finished product.Every capsules 450mg.
Characteristics of the present invention are:
1, medicine of the present invention is that the main material selected for use all has the living body biological material of certain curative effect to cardiovascular system diseases and extracts, makes up under the reasonable process condition, make the medicine biological activity height of preparation, the effective ingredient cooperative effect of organism adaptation is good, and the treatment cardiovascular system diseases is played advantages such as quick-acting, long-lasting and short treating period.
2, medicine of the present invention is nutritious, without any side effects to human liver, renal function, detect according to Fujian Province Institute of Analysis and China National Light Industrial Products Department food station, Foochow, inspection center, this product is rich in the necessary natural bioactivity substance of human body: 1. oral liquid contain reducing sugar 3.9%, polysaccharide 0.56%, nucleic acid 0.13% crude fat 0.1%, unsaturated fatty acid total amount account for the total fatty acids amount 68.6%, 19 kind of free amino acid total amount 15.08mg/ml and vitamin B
1, E, B
2, tens kinds of trace element such as C, D and germanium thereof, selenium, iodine, zinc, chromium; 2. capsule contain 19 kinds of free amino acid total amount 6.47% protein 〉=38%, crude fat 9.6%, unsaturated fatty acid total amounts account for the total fatty acids amount 71.8%, nucleic acid 1%, polysaccharide 0.42% and vitamin B
1, B
2, tens kinds of trace element such as C, E, D and germanium thereof, selenium, iodine, zinc, chromium; These materials are directly absorbed by human body easily, participate in the important metabolism effect of body, and to strengthening human body constitution, disease resistance enhancemen also has quick-acting, long-lasting important function.
3, medicine of the present invention all has significant curative effect to the heart and the blood vessel two big class diseases of cardiovascular system, and at normal index patient is had significantly two-wayly to the normal value regulatory function, for example Sodium Ferulate, channels spirit, SUXIAO JIUXIN WAN, fungus nafenopin, soft pulse spirit etc. all are single therapy or only to heart or only treat the shortcoming of use at certain disease of blood vessel to have overcome more existing these type of medicines; In addition multiple medicine mixes curative effect, still exists dosage between the medicine to the inharmonious shortcoming of controlling of entangling of patient, also has side reaction or extends the period of treatment.
4, medicine of the present invention has added the Bulbus Allii piece and the ginger slice of live body in extraction process, make and be added with Rhizoma Zingiberis Recens Bulbus Allii working substance in the drug ingredient that makes, strengthened the sterilization and anticorrosion effect of drug storage phase, and strengthened the biological active matter mass effect of medicine, play the auxiliary treatment effect to entangling the treating rheumatic cardiovascular disease.
5, medicine of the present invention has added plurality of enzymes bodies such as egg albumen (interior lysozyme), cellulase, papain and pectase in extraction process, improved the dissolved cell wall effect effectively, extraction time has been shortened, and the cell inclusion stripping quantity has increased, saved raw material, and drug quality is guaranteed.
6, medicine of the present invention also all has produce effects to other human bodies are ailing as toothache, carsickness, stomach discomfort etc. except that cardiovascular system diseases being had the broad spectrum activity produce effects.
7, process for preparing medicine of the present invention is scientific and reasonable, and equipment is simple, and raw material is easy to get, and has higher economic results in society.
8, by specific embodiment and clinical effectiveness checking scientific rationality of the present invention is described.
Embodiment 1, get the Ganoderma of above-mentioned cultivation, JINZHENGU, the mycelium of Poria (containing the beans culture medium) each 15%, get the above-mentioned Volvariella volvacea (Bull.Ex Franch.) Singer of having cultivated, the blood sesame, Auricularia, hypha of Pleurotus ostreatus body (containing the beans culture medium) each 10%, get the above-mentioned Hericium erinaceus (Bull. Ex Fr.) Pers. of having cultivated, mushroom, Lentinus Edodes, each 5% mix to form the mycelium of Tremella (containing the beans culture medium) mycelium class raw material (being called for short category-A down) and measures Ganoderma by above-mentioned, JINZHENGU, Poria, Volvariella volvacea (Bull.Ex Franch.) Singer, the blood sesame, Auricularia, Pleurotus ostreatus, mushroom, Lentinus Edodes, Tremella, the bright product of the spore entity that do not fall of Hericium erinaceus (Bull. Ex Fr.) Pers. fungus are chopped into lamellar and are mixed into sporophore class raw material (being called for short category-B down), be dissolved with by cellulase 0.2% putting into after category-A raw material and the category-B raw material mixed in equal amounts, papain 0.2%, pectase 0.5%, contain vinegar 0.5%, egg albumen 0.5%, Rhizoma Zingiberis Recens fragment 3%, in the stainless steel water bath of the lixiviating solution that Bulbus Allii fragment 3% and distilled water are formed, regulate pH value 4.5 with Vc, carrying out extracting technology 60 ℃ of left and right sides temperature concentrates the lixiviating solution warp again, be mixed with oral liquid, through the angiocardiopathy institute, Fujian Province the cardiovascular system diseases patient carried out clinical taking and show: one, this product is to dizziness, cardiopalmus, uncomfortable in chest, weak doing well,improving rate reaches more than 90%; Ischemia electrocardiogram improvement rate is reached 80%, and room improvement rate early reaches 100%.For example Liu * *, woman, 55 years old, she suffers from dizzy, uncomfortable in chest, tachypnea symptom more than 8 years, electrocardiogram T: I, II dVF V
5-6Low flat, inversion, (medicine) being taken before meal this product 30ml/ time, 3 times/day, symptom complete obiteration after 2 courses of treatment in week, electrocardiogram is normal.Two, this product improves SOD (superoxide dismutase)/MDA ratio (P＜0.05) and all has remarkable and extremely remarkable effect, and the SOD of raising effect is arranged reducing MDA (malonaldehyde) (P＜0.01).For example: patient king * * man, 58 years old, dizziness, cardiopalmus, uncomfortable in chest, SOD142ng/ml, MDA8.33nm/ml; Take transference cure after the courses of treatment in this product 2 week, SOD is 271ng/ml, and MDA6.21nm/ml significantly improves SOD value, reduction MDA value.Three, this product has dual regulation to platelet aggregation, promptly has high aggregation rate to reduce (P＜0.01) concerning same patient and improves (P＜0.01) with low aggregation rate.For example: journey * *, woman 60 years old, platelet aggregation rate is unusual, shows as 1 clinically ' be 7.65%, 3 ' be 100%, 5 ' be 1001%, (medicine) being taken before meal 3 times/day, is measured platelet aggregation rate after 2 all courses of treatment with this product 30ml/ time; 1 ' be 12.94%, 3 ' be 32.16%, 5 ' be 44.31%, all meet normal value.Four, to improving hemorheology remarkable result is arranged.For example patient Yao * *, woman, 52 years old, high shear 9.35, low shear 10.11, low cutting reduces 17.60, plasma viscosity 1.96, Fibrinogen 7.0 is taken this product after two weeks, high shear 6.14, low shear 8.10, low reduction 15.60, the plasma viscosity 1.80 cut, Fibrinogen 6.0, each value of its hemorheology is greatly improved.Five, this product also all has remarkable result to blood fat reducing, high density lipoprotein increasing.Patient Liu * *, woman, 65 years old, T
c6.8mmol/L, HDL-ch1.33mmol/L, H/C20%, TG1.1mmol/L takes this product after 2 weeks, T
cReduce to 5.5mmol/L, HDL-ch is upgraded to 1.63, and H/C is 24%, TG1.3mmol/L.Six, to reducing hypertension positive effect is arranged.For example the king * *, the man, 58 years old, arteriotony 160-145/90-100mmHg, taking this product 2 all bleeding from anus pressure drops is 140-130/90-75mmHg.
Embodiment 2, get the above-mentioned Volvariella volvacea (Bull.Ex Franch.) Singer of having cultivated, the blood sesame, Auricularia, hypha of Pleurotus ostreatus body (containing the beans culture medium) each 5%, get the above-mentioned Ganoderma of having cultivated, JINZHENGU, Poria mycelium (containing the beans culture medium) each 10%, Hericium erinaceus (Bull. Ex Fr.) Pers., mushroom, Lentinus Edodes, tremella mycelium (containing the beans culture medium) each 15%, be mixed into the category-A raw material, measure each above-mentioned fungus sporophore fragment equally and be mixed into the category-B raw material, with category-A, the category-B mixed in equal amounts is put into water-bath, pours into by cellulase 0.2%, papain 0.3%, pectase 0.5% contains vinegar 1%, egg albumen 2%, Rhizoma Zingiberis Recens fragment 3%, Bulbus Allii fragment 4%, adding distil water to the lixiviating solution of percentage by weight 100% floods raw mix to soaking, and regulates PH to 5 with Vc, get extract 3 times 55 ℃ of temperature left and right sides lixiviates, through concentrate concentrated solution, make this product capsule by above-mentioned technology.This product is splendid through angiocardiopathy institute, Fujian Province clinical application effect.One, to dizzy, uncomfortable in chest, cardiopalmus, hole improvement rate early 〉=93%, ischemia electrocardiogram improvement rate reaches 75%, and room improvement rate early reaches 90%.For example: Wu * *, the man, 34 years old, it was surplus to show as dizziness, headache, uncomfortable in chest, chest pain, cardiopalmus two months before taking medicine, the electrocardiogram hole is slow, limb connection low-voltage, takes this capsule by 6/time, 3 times/day, (medicine) being taken before meal with 2 weeks after, it is normal that transference cure, electrocardiogram recover.Two, to reducing MDA, improve SOD and have the significance effect.For example: Liu * *, the woman, 55 years old, MDA9.2nm/ml before the clothes, SOD200ng/ml takes this capsule, and by 6/time, 3 times/day, (medicine) being taken before meal is measured MDA4.7nm/mlSOD337ng/ml with 2 all backs, all is greatly improved.Three, this product has dual regulation to platelet aggregation.For example: old * *, man 67 years old, platelet aggregation is 1 ' 68.98%, 3 unusually ' be 100%, 5 ' be 71.95%, take this product by 6/time, 3 times/day, (medicine) being taken before meal with 2 weeks after, record 1 ' be 15.29%, 3 ' be 21.20%, (5 ') are 35.30%, platelet aggregation rate transfers normal value to.For another example: the king * *, the man, it is unusual to suffer from platelet aggregation rate, take medicine preceding 1 ' be 0%, 3 ' be 0%, 5 ' be 8.39%, (medicine) being taken before meal with 2 weeks of this product (6/time, 3 times/day) after, record 1 ' be 42.55%, 3 ' be 10.03%, 5 ' 20.75%, platelet aggregation rate takes a turn for the better to some extent.Four, this product has remarkable result to improving hemorheology.For example: old * *, man 80 years old records high shear 6.84 before taking medicine, low shear 9.11, low reduction 18.02, the plasma viscosity 1.92 cut, Fibrinogen 6.6, by 6/time, 3 times/day, (medicine) being taken before meal with 2 weeks after, record high shear 6.25, low shear 9.84, low cutting reduces 10.20, plasma viscosity 1.78, Fibrinogen 6.0, hemorheology have significance to improve.Five, this product has positive effect to blood fat reducing and raising high density lipoprotein.For example Lee * *, the woman, 52 years old, before taking medicine, T
c6.5mmol/L, HDL-ch1.2mmol/LH/c18%, TG3.6mmol/L, by 6/time, 3 times/day, (medicine) being taken before meal with 2 weeks after, record T
c5.9mmol/L, HDL-cn1.7mmol/L, H/C28%TG2.4mmol/L.Six, this product has the two-ways regulation effect to arteriotony, for example: old * *, the man, 24 years old, blood pressure 90/60mmHg, by 6/time, 3 times/day, (medicine) being taken before meal with 2 weeks after, blood pressure regulating is 105/70mmHg; For another example woods * *, the man, 67 years old, blood pressure 180/110mmHg before taking medicine, by 6/time, 3 times/day, (medicine) being taken before meal is 135/90mmHg with 2 all bleeding from anus pressure drops, the recovery range of normal value.
From above two embodiment and clinically effect all can show, Drug therapy cardiovascular system diseases with the inventive method preparation, no matter be the improvement that feels from the clinical patients symptom, still show improvement by instrument to the electrocardiogram myocardial ischemia, to the room early, hole improvement early all has very significant effect, it can improve the microcirculation in human body system effectively, improved the capacity for work of each important organ of human body, the balance of human homergy's function and interior environment is restored, and it is fast also to have curative effect clinically, produce effects speed, characteristics such as broad spectrum activity is strong.
Claims (2)
1, a kind of cardiovascular system diseases medicine, the material medicine that it is characterized in that this medicine is by Ganoderma, Auricularia, Poria, Volvariella volvacea (Bull.Ex Franch.) Singer, the blood sesame, mushroom, JINZHENGU, Lentinus Edodes, Hericium erinaceus (Bull. Ex Fr.) Pers., Pleurotus ostreatus, each plant demand of the mycelium of Tremella is 5-15%, Ganoderma, Auricularia, Poria, Volvariella volvacea (Bull.Ex Franch.) Singer, the blood sesame, mushroom, JINZHENGU, Lentinus Edodes, Hericium erinaceus (Bull. Ex Fr.) Pers., Pleurotus ostreatus, each plant demand of live body sporophore of Tremella is 5-15%, Semen Glycines, Semen sojae atricolor, Semen phaseoli radiati, Semen arachidis hypogaeae, each plant demand of Semen Phaseoli is that the beans culture medium zymolite of 5-15% composition is formulated, its step of preparation process comprises bacterial strain choosing cultivation, the preparation of beans culture medium, mycelium is cultivated, sporophore is chosen, the material medicine preparation, lixiviate, concentrate, finished product is made, wherein the preparation of beans culture medium is the Semen Glycines of cleaning with germinating capacity, Semen sojae atricolor, Semen phaseoli radiati, Semen arachidis hypogaeae, Semen Phaseoli equivalent is under 20 ℃ of conditions, soaking 48 hours drops anhydrates behind the branch, add calcium sulfate, glucose each 2%, the PH nature, behind the mix homogeneously, sterilized 60 minutes through 1.1Kg/Cm in the packaging container, cooling forms, the lixiviating solution prescription is by cellulase in the extracting technology, papain, each 0.1-0.5% of pectase, vinegar, each 0.5-2.0% of egg albumen, the Rhizoma Zingiberis Recens fragment, each 1-6% of Bulbus Allii fragment, adding distil water to 100%.
2, medicine according to claim 1, it is characterized in that it is to put stainless steel disc at-0.1MPA vacuum, 65 ℃ of temperature dryings at concentrated solution that capsule in the finished product processing technology is made, be ground into powdery, add 8%Vc powder mix homogeneously rear packing again, form through 65 ℃ of sterilization treatment again.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96102904A CN1064263C (en) | 1996-02-16 | 1996-02-16 | Suxiao Xinmaisu drug for curing angiocardiopathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96102904A CN1064263C (en) | 1996-02-16 | 1996-02-16 | Suxiao Xinmaisu drug for curing angiocardiopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1157171A CN1157171A (en) | 1997-08-20 |
| CN1064263C true CN1064263C (en) | 2001-04-11 |
Family
ID=5117783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96102904A Expired - Fee Related CN1064263C (en) | 1996-02-16 | 1996-02-16 | Suxiao Xinmaisu drug for curing angiocardiopathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1064263C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5939072A (en) * | 1998-05-13 | 1999-08-17 | Zhou; James H. | Herbal composition and method of treating viral infection of the liver |
| WO2001044488A1 (en) * | 1999-12-15 | 2001-06-21 | Amino Up Chemical Co., Ltd. | Novel substance originating in basidiomycete culture, process for producing the same and use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1077638A (en) * | 1992-04-14 | 1993-10-27 | 郝超焰 | Preparation method of oral nutritional medicine for pregnant women |
| CN1083099A (en) * | 1992-08-19 | 1994-03-02 | 管代义 | Process for producing spirit of north Chinese cater pillar fungus |
-
1996
- 1996-02-16 CN CN96102904A patent/CN1064263C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1077638A (en) * | 1992-04-14 | 1993-10-27 | 郝超焰 | Preparation method of oral nutritional medicine for pregnant women |
| CN1083099A (en) * | 1992-08-19 | 1994-03-02 | 管代义 | Process for producing spirit of north Chinese cater pillar fungus |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1157171A (en) | 1997-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2689951C1 (en) | Mushrooms production method | |
| CN101624570B (en) | Method for cultivating cultured ganoderma lucidum with Chinese medicaments and method for preparing cultured ganoderma lucidum health-care product | |
| CN108753874A (en) | A kind of preparation method of small active peptides novel spirulina powder | |
| CN106212046A (en) | A kind of Ganoderma breeding method and the method for manufactured meat Ganoderma water | |
| KR20190009884A (en) | Manufacturing method of fermented health food using slugs | |
| CN107593955A (en) | Ferment edible mushroom tea preparation process and fermentation edible mushroom tea | |
| KR20020003165A (en) | Process for Producing a fermented food for health aid | |
| CN1331908A (en) | Chinese herbal medicinal edible fungus culture medium and edible fungus producing method with the culture medium | |
| CN102488278A (en) | Composite fungus nutrient solution with bifunctional health care effect | |
| CN102600443B (en) | Combination capable of improving immunity and preparation method and application | |
| CN107652048A (en) | A kind of cultivation matrix of mushroom enhancing immunization and preparation method thereof | |
| CN108243837A (en) | A kind of culture medium of selenium-enriched edible mushroom and preparation method thereof | |
| CN101283799A (en) | Preparation method of health food for adjusting the blood fat | |
| Stengler | Health benefits of medicinal mushrooms | |
| CN1826866A (en) | Method for planting common fig or fiveleaf gynostemma herb with enriched microelement and uses thereof | |
| CN1064263C (en) | Suxiao Xinmaisu drug for curing angiocardiopathy | |
| WO1995018626A1 (en) | A tonic drug made from basidiomycetes, algae, chinese herbal medicine and the method thereof | |
| KR100838705B1 (en) | Mushroom fermentation, preparing method and use thereof | |
| CN100488381C (en) | Propolis ganoderma lucidum spore, dried black fungus polysaccharide compounded soft capsule and preparing process therefor | |
| JP3509736B2 (en) | A method for preparing a fungus bed of Physcomitrella patens having physiological functions | |
| CN109527577A (en) | A kind of composition with sobering up and liver protecting functions | |
| CN107997125A (en) | Edible mushroom mycelium and or edible mushroom mycelium powder manufacture craft and products thereof | |
| CN107960351A (en) | Leech high yield artificial cultivating method | |
| KR100442766B1 (en) | Artificial method to culture Cordyceps Kyushuensis Y.Kobayas and the application for its sporocarp | |
| CN106954855A (en) | A kind of anticancer composite fungi amylose and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |